CN103435697A - 流感病毒的中和抗体 - Google Patents

流感病毒的中和抗体 Download PDF

Info

Publication number
CN103435697A
CN103435697A CN2013102549131A CN201310254913A CN103435697A CN 103435697 A CN103435697 A CN 103435697A CN 2013102549131 A CN2013102549131 A CN 2013102549131A CN 201310254913 A CN201310254913 A CN 201310254913A CN 103435697 A CN103435697 A CN 103435697A
Authority
CN
China
Prior art keywords
influenza
antibodies
antibody
virus
subtype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2013102549131A
Other languages
English (en)
Chinese (zh)
Inventor
拉梅什.R.巴特
劳伦斯.霍罗威茨
阿伦.K.卡什亚普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sea Lane Biotechnologies LLC
Original Assignee
Sea Lane Biotechnologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sea Lane Biotechnologies LLC filed Critical Sea Lane Biotechnologies LLC
Publication of CN103435697A publication Critical patent/CN103435697A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN2013102549131A 2006-05-15 2007-05-15 流感病毒的中和抗体 Pending CN103435697A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80078706P 2006-05-15 2006-05-15
US60/800,787 2006-05-15
US85567906P 2006-10-30 2006-10-30
US60/855,679 2006-10-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800258774A Division CN101495511A (zh) 2006-05-15 2007-05-15 流感病毒的中和抗体

Publications (1)

Publication Number Publication Date
CN103435697A true CN103435697A (zh) 2013-12-11

Family

ID=38694784

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2013102549131A Pending CN103435697A (zh) 2006-05-15 2007-05-15 流感病毒的中和抗体

Country Status (8)

Country Link
US (4) US20080014205A1 (https=)
EP (2) EP2024393A2 (https=)
JP (2) JP2009537147A (https=)
CN (1) CN103435697A (https=)
AU (1) AU2007249160B2 (https=)
CA (1) CA2652452C (https=)
IL (3) IL195225A (https=)
WO (1) WO2007134327A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109923125A (zh) * 2016-08-25 2019-06-21 牛津大学创新有限公司 免疫原性组合物
CN113173990A (zh) * 2014-07-15 2021-07-27 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148085B2 (en) * 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
WO2008110937A2 (en) * 2007-03-13 2008-09-18 Humabs Llc Antibodies against h5n1 strains of influenza a virus
CN101679974B (zh) 2007-03-27 2015-09-30 航道生物技术有限责任公司 包含抗体替代轻链序列的构建体和文库
CA2684103A1 (en) * 2007-04-11 2008-10-23 Immuron Limited Delivery of flu antibodies to surfaces in contact with air
RU2010127156A (ru) 2007-12-06 2012-01-20 Дана-Фарбер Кэнсер Инститьют, Инк. (Us) Антитела против вируса гриппа и их применение
ITTO20080204A1 (it) * 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
JP2011516423A (ja) * 2008-03-28 2011-05-26 シー レーン バイオテクノロジーズ， エルエルシー ウイルス抗原に対する中和分子
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
CA2731686C (en) * 2008-07-25 2020-04-07 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
GB0818356D0 (en) * 2008-10-07 2008-11-12 Istituto Superiore Di Sanito Antibodies
CA2741435A1 (en) * 2008-10-21 2010-04-29 Novartis Ag Immunization protocol for directed expansion and maturation
PL2350128T3 (pl) 2008-10-22 2015-03-31 Inst Res Biomedicine Sposoby wytwarzania przeciwciał z komórek plazmatycznych
ITTO20080964A1 (it) 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
CA2761648C (en) 2009-05-11 2019-03-12 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
CA2761681A1 (en) * 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
US8673314B2 (en) 2009-05-26 2014-03-18 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
EP2536425B1 (en) 2010-02-18 2019-06-19 Icahn School of Medicine at Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
KR101849738B1 (ko) 2010-06-17 2018-04-17 트렐리스 바이오싸이언스 인코포레이티드 수동 인플루엔자 면역에 유용한 항체
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
EP2436766A1 (en) * 2010-09-29 2012-04-04 Deutsches Krebsforschungszentrum Means and methods for improved protein interaction screening
WO2012045001A2 (en) * 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
EP2640831A1 (en) 2010-11-17 2013-09-25 Sea Lane Biotechnologies,llc. Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
AU2011373387B2 (en) 2011-07-18 2017-06-29 Institute For Research In Biomedicine Neutralizing anti-influenza A virus antibodies and uses thereof
EP2736928B1 (en) 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Sur-binding proteins against erbb3
EP4241785B1 (en) 2011-09-20 2026-01-28 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
JP5998222B2 (ja) 2011-09-30 2016-09-28 セルトリオン・インコーポレイテッド ヒトｂ細胞で生産されたインフルエンザａウイルス中和活性を持つ結合分子
KR20130059721A (ko) * 2011-11-29 2013-06-07 (주)셀트리온 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자
MX367743B (es) 2011-12-05 2019-09-04 Trellis Bioscience Llc Anticuerpos utiles para la inmunizacion pasiva de influenza.
WO2013089496A1 (ko) * 2011-12-15 2013-06-20 (주)에이프로젠 H1n1-감염된 환자들로부터 유도된 매우 잠재력 있는 넓은-스펙트럼 중화 단일클론 항체 및 이를 포함하는 바이러스의 치료용 조성물
US9975956B2 (en) 2011-12-22 2018-05-22 I2 Pharmaceuticals, Inc. Surrogate binding proteins which bind DR4 and/or DR5
WO2013119683A1 (en) * 2012-02-07 2013-08-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
JP6628966B2 (ja) 2012-06-14 2020-01-15 中外製薬株式会社 改変されたＦｃ領域を含む抗原結合分子
SG11201504728RA (en) 2012-12-18 2015-07-30 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
MX387277B (es) 2013-03-14 2025-03-12 Contrafect Corp Composiciones basadas en anticuerpos neutralizantes suministrados intranasalmente para eficacia terapéutica aumentada.
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US9101597B2 (en) 2013-03-14 2015-08-11 The Administration Of The Tulane Educational Fund Immunoprotective primary mesenchymal stem cells and methods
EP3037533A4 (en) 2013-08-23 2017-07-05 Fujita Health University Anti-influenza virus-neutralizing antibody
SI3052192T1 (sl) 2013-10-02 2020-11-30 Medimmune, Llc Nevtralizarijoča protitelesa proti-influenci A in njihove uporabe
KR102813659B1 (ko) 2013-11-11 2025-05-28 추가이 세이야쿠 가부시키가이샤 개변된 항체 가변영역을 포함하는 항원 결합 분자
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
JP6712428B2 (ja) 2014-02-04 2020-06-24 コントラフェクト コーポレイション インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法
EP4050026A1 (en) 2014-04-01 2022-08-31 Adimab, LLC Method of obtaining or identifying one or more common light chains for use in preparing a multispecific antibody
TWI831044B (zh) 2014-11-11 2024-02-01 日商中外製藥股份有限公司 抗原結合分子、包含抗原結合分子的醫藥組合物以及製造及選擇抗原結合分子之方法
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
HUE056407T2 (hu) 2015-06-01 2022-02-28 Medimmune Llc Neutralizáló influenzaellenes kötõmolekulák és alkalmazásaik
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
SG11201805001UA (en) 2016-01-13 2018-07-30 Medimmune Llc Method of treating influenza a
AU2017222564A1 (en) 2016-02-24 2018-09-06 Visterra, Inc. Formulations of antibody molecules to influenza virus
MX2018015755A (es) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
PL3532612T3 (pl) * 2016-10-31 2022-10-31 Universität Zürich Kolekcja znaczników i sposoby detekcji białek, korzystnie za pomocą spektrometrii masowej
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
US11434277B2 (en) 2017-10-20 2022-09-06 Academia Sinica Method for high-throughput screening of neutralizing antibodies, neutralizing antibodies produced therefrom, and uses thereof
TW201938194A (zh) 2017-12-05 2019-10-01 日商中外製藥股份有限公司 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子
CA3104297A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
MX2021000827A (es) 2018-08-03 2021-03-25 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno que contiene dos dominios de union a antigeno que estan enlazados entre si.
US12509524B2 (en) 2018-09-28 2025-12-30 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region
US11230593B2 (en) 2019-03-25 2022-01-25 Visterra, Inc. Compositions and methods for treating and preventing influenza
US12545718B2 (en) 2019-04-24 2026-02-10 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
EP4031558A4 (en) * 2019-09-20 2023-05-31 Academia Sinica CHIMERIC HEMAGGLUTININ PROTEIN AND VACCINE COMPOSITION COMPRISING THEM
CR20220541A (es) 2020-03-31 2022-11-28 Chugai Pharmaceutical Co Ltd Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta 3 (dll3) y sus usos
CN113121680B (zh) * 2021-04-12 2022-03-29 华南农业大学 一种抗h5亚型禽流感纳米抗体蛋白及其编码基因与应用
CN113355344B (zh) * 2021-08-10 2021-11-02 北京溯本源和生物科技有限公司 一种流感病毒ns1蛋白的表达质粒、重组蛋白和特异性单克隆抗体及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984000687A1 (en) * 1982-08-23 1984-03-01 Scripps Clinic Res Broad spectrum influenza antisera
US20020054882A1 (en) * 1992-09-17 2002-05-09 Yoshinobu Okuno Anti-human influenza virus antibody

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
ATE114723T1 (de) 1987-03-02 1994-12-15 Enzon Lab Inc Organismus als träger für ''single chain antibody domain (scad)''.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
ES2038579T3 (es) 1989-04-28 1997-02-16 Rhein Biotech Proz & Prod Gmbh Celulas de levadura del genero schwanniomyces.
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2079802C (en) 1990-04-05 2001-09-18 Roberto Crea Walk-through mutagenesis
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5667988A (en) * 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
WO1993016177A1 (en) 1992-02-11 1993-08-19 Cell Genesys, Inc. Homogenotization of gene-targeting events
JP3037554B2 (ja) * 1993-04-20 2000-04-24 寳酒造株式会社 免疫原性人工ポリペプチド
US20030194807A1 (en) 1992-11-02 2003-10-16 Roberto Crea Walk-through mutagenesis
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
WO2000057183A1 (en) * 1999-03-23 2000-09-28 Biovation Limited Protein isolation and analysis
FR2817869B1 (fr) * 2000-12-07 2005-01-14 Technopharm Anticorps monoclonal humain dirige contre le virus influenza ou un fragment de celui-ci
WO2002061071A2 (en) * 2000-12-18 2002-08-08 Dyax Corp. Focused libraries of genetic packages
CA2478973A1 (en) * 2002-03-13 2003-09-25 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
JP4493347B2 (ja) 2002-04-17 2010-06-30 ロベルト クレア 免疫グロブリンのユニバーサルライブラリー
CA2484930A1 (en) * 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
BRPI0412007A (pt) 2003-06-27 2006-08-15 Bioren Inc mutagênese look-through
AU2004286201B2 (en) * 2003-09-10 2010-09-09 Altheadx, Inc. Expression profiling using microarrays
US7566454B2 (en) * 2005-02-24 2009-07-28 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
CA2622603C (en) * 2005-09-15 2014-06-17 Crucell Holland B.V. Method for preparing immunoglobulin libraries
GB0522460D0 (en) * 2005-11-03 2005-12-14 Prendergast Patrick T Composition and method for the treatment of avian influenza
WO2007089753A2 (en) * 2006-01-26 2007-08-09 Hx Diagnostics, Inc. Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984000687A1 (en) * 1982-08-23 1984-03-01 Scripps Clinic Res Broad spectrum influenza antisera
US20020054882A1 (en) * 1992-09-17 2002-05-09 Yoshinobu Okuno Anti-human influenza virus antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Y.A.SMIRNOV ET.AL: "An epitope shared by the hemagglutinins of H1,H2,H5 and H6 subtypes of influenza a virus", 《ACTA VIROLOGICA》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113173990A (zh) * 2014-07-15 2021-07-27 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
CN109923125A (zh) * 2016-08-25 2019-06-21 牛津大学创新有限公司 免疫原性组合物
CN109923125B (zh) * 2016-08-25 2024-05-31 牛津大学创新有限公司 免疫原性组合物

Also Published As

Publication number Publication date
CA2652452A1 (en) 2007-11-22
AU2007249160A1 (en) 2007-11-22
US20100316654A1 (en) 2010-12-16
JP2013067660A (ja) 2013-04-18
IL195225A (en) 2015-06-30
AU2007249160B2 (en) 2013-09-12
CA2652452C (en) 2018-07-31
WO2007134327A3 (en) 2008-10-02
JP2009537147A (ja) 2009-10-29
US20120107326A1 (en) 2012-05-03
EP2024393A2 (en) 2009-02-18
IL222762A0 (en) 2012-12-31
US20140205614A1 (en) 2014-07-24
WO2007134327A2 (en) 2007-11-22
EP2522678A1 (en) 2012-11-14
IL195225A0 (en) 2011-08-01
US20080014205A1 (en) 2008-01-17
IL239023A0 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
AU2007249160B2 (en) Neutralizing antibodies to influenza viruses
US10017561B2 (en) Neutralizing molecules to influenza viruses
US9169318B2 (en) Neutralizing molecules to viral antigens
US20080152657A1 (en) Donor specific antibody libraries
CN101495511A (zh) 流感病毒的中和抗体
HK1192256A (en) Neutralizing antibodies to influenza viruses
HK1133895A (en) Neutralizing antibodies to influenza viruses
HK1195318A (en) Neutralizing molecules to viral antigens
HK1171463A (en) Neutralizing molecules to influenza viruses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1192256

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20131211

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1192256

Country of ref document: HK